Christopher Bernard, Chris Emery
Curetis announced that Christopher Bernard has resigned as CEO and president of Curetis USA, as well as from the firm's management board, effective Aug. 31. The company has appointed Chris Emery to replace him, effective Sept. 1.
Bernard joined Curetis USA as CEO and president in July 2016 and had served on Curetis NV's management board since June 2018.
Emery has more than 20 years of commercial experience in the diagnostic and pharmaceutical industries. Prior to Curetis, Emery served as chief commercial officer of North America for Menarini Silicon Biosystems, where he directed US sales and business development activities for the DepArray Nxt molecular device and integrated the CellSearch Circulating Tumor Cell test. He has also served as general manager for Abbott's PersonalizeDx cancer diagnostics laboratory division and has held senior level management roles at CombiMatrix, Response Genetics, and US Labs.